Clinical Trial Search

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml

Primary: Disposition Index — 0.023; 0.149 index

Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements. — 13.70; -3.67; 6.64; 1.66 mg/dL — p=0.0117

Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: CGM Time Below 54 mg/dL — 0.00; 0.00; 0.00; 0.00 percentage of time

Primary: % Participants Downloading Huma App — 95; 0 Participants

Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60

Primary: Program Enrollment Rate (%) — 14 Percentage of participants

Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants

Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population — -2.01; -1.75 percent — p=<0.0001

Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: Change in Insulin Sensitivity — 3.18; 3.85; 3.57; 5.22 mg/kg.min per µU/ml

Primary: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care — -0.16; -0.12 liters

Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1

Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: Program Enrollment Rate (%) — 6.1 percentage of invitees

Primary: Change in Absolute Gluconeogenesis From Baseline to 12 Weeks — 0.018; -0.050 mg/kg LBM/min

Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants

Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min